Paraoxonase-1 and Simvastatin Treatment in Patients with Stable Coronary Artery Disease
Table 2
Lipid profile, concentrations of selected markers of inflammation, oxidative stress, FMD, and IMT in patients and controls before and after treatment with simvastatin.
CAD group
Controls
At baseline
After 6 months
After 12 months
At baseline
After 12 months
Number of subjects; females
53 (9)
53 (9)
53 (9)
53 (6)
53 (6)
Total cholesterol; mmol/L
6.02 ± 0.81£
4.54 ± 0.73¥
4.97 ± 0.97
0.000001
5.18 ± 0.95
5.26 ± 0.94
0.69
LDL cholesterol; mmol/L
3.79 ± 0.76£
2.36 ± 0.64¥
2.85 ± 0.82
0.000001
2.93 ± 0.73
3.08 ± 0.75
0.46
HDL cholesterol; mmol/L
1.29 ± 0.34
1.36 ± 0.46
1.35 ± 0.44
0.32
1.32 ± 0.41
1.27 ± 0.34
0.44
Triglycerides; mmol/L
2.11 ± 1.05
1.83 ± 1.1
1.77 ± 0.95
0.06
2.01 ± 1.42
2.2 ± 2.47
0.51
Fibrinogen; g/L
3.73 ± 1.02£
3.93 ± 1.19
3.85 ± 1.19
0.65
3.34 ± 0.74
3.26 ± 0.87
0.98
hs-CRP; mg/L
2.93 ± 2.53£
1.57 ± 1.46¥
1.67 ± 1.19
0.021
1.31 ± 1.14
1.34 ± 1.54
0.81
TNF-α; pg/mL
1.82 ± 1.41£
1.66 ± 1.32
1.31 ± 0.95
0.001
0.85 ± 0.45
0.88 ± 0.43
0.67
8-Iso-PGF2α; pg/mg creat.
1305.2 ± 817.1£
1333.0 ± 829.5
1285.5 ± 790.3
0.86
572.6 ± 314.8
547.49 ± 306.8
0.79
FMD; %
6.76 ± 2.53£
8.25 ± 3.3¥
8.12 ± 2.28
0.0004
8.08 ± 2.8
8.26 ± 3.12
0.47
IMT; mm
0.7 ± 0.14£
0.64 ± 0.14¥
0.63 ± 0.16
0.008
0.57 ± 0.08
0.55 ± 0.08
0.27
Data is presented as arithmetic means ± SD; Student’s -test; Mann-Whitney test; ANOVA Friedman test; Wilcoxon signed-rank test; , after 6 months of treatment compared to baseline; , after 12 months of treatment compared to baseline; , after 12 months of treatment compared to controls; , at baseline compared to controls.
